« Back
Home /
PF-AKT400

PF-AKT400

Item no.	HY-10721-10mM
Manufacturer	MedChem Express
CASRN	1004990-28-6
Amount	10mM/1mL
Quantity options	100 mg 10mM/1mL 10 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Testicular & Prostate Cancer
Type	Inhibitors
Specific against	other
Purity	98.0
Formula	C20H22F2N6O
Citations	[1]Chen SF, et al. Binding selectivity studies of PKBα using molecular dynamics simulation and free energy calculations. J Mol Model. 2013 Nov;19(11):5097-5112.<br/>[2]Freeman-Cook KD, et al. Design of selective, ATP-competitive inhibitors of Akt. J Med Chem. 2010 Jun 24;53(12):4615-4622.
Smiles	N[C@@](CC1)(CNC(C2=CC=C(F)C=C2F)=O)CN1C3=C4C(NC=C4CC)=NC=N3
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	AKT protein kinase inhibitor
Available
Product Description	PF-AKT400 is a broadly selective, potent, ATP-competitive Akt inhibitor, displays 900-fold greater selectivity for PKBα (IC50=0.5 nM) than PKA (IC50=450 nM).
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	400.43
Clinical Information	No Development Reported
Manufacturers Research Area	Cancer
Solubility	DMSO : ≥ 100 mg/mL
Target	Akt
Manufacturers Target	Akt
Isoform	Akt1
Manufacturers Pathway	PI3K/Akt/mTOR
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10721-10mM-safety-datasheet.pdf